Filter results
01/08/2022
ROVI has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
27/07/2022
ROVI reports operating revenue growth of 31% and net profit growth of 58%
19/07/2022
EIB and ROVI are signing a EUR 50 million loan agreement in Madrid for research, development and innovation.
11/05/2022
ROVI reports operating revenue growth of 57% and net profit growth of 123%
08/04/2022
Moderna and ROVI Pharma Industrial Services, S.A.U. today announced a recall of one lot (lot #000190A) of the Moderna COVID-19 vaccine (Spikevax®)
04/03/2022
The achievement of this important milestone responds to the Environmental and Social Sustainability Policy of the Group and to the efforts that performs to reduce the environmental impact of all its activities.
23/02/2022
ROVI reports operating revenue growth of 54% and net profit growth of 151%
16/02/2022
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain
15/02/2022
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone